SI-BONE INC (SIBN) Stock Price, Quote, News and Overview
NASDAQ:SIBN - Nasdaq - US8257041090 - Common Stock - Currency: USD
SIBN Quote, Performance and Key Statistics
15.46
+0.16 (+1.05%)
The current stock price of SIBN is 15.46 USD. In the past month the price decreased by -6.98%. In the past year, price increased by 11.46%.
SIBN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.89 | 229.22B | ||
| ISRG | INTUITIVE SURGICAL INC | 59.66 | 172.16B | ||
| BSX | BOSTON SCIENTIFIC CORP | 36.46 | 152.63B | ||
| SYK | STRYKER CORP | 29.72 | 145.95B | ||
| MDT | MEDTRONIC PLC | 16.91 | 119.18B | ||
| BDX | BECTON DICKINSON AND CO | 13.73 | 56.16B | ||
| IDXX | IDEXX LABORATORIES INC | 54.19 | 52.34B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30.45 | 45.95B | ||
| RMD | RESMED INC | 29.83 | 41.77B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.75 | 33.61B | ||
| DXCM | DEXCOM INC | 47.62 | 31.74B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.35 | 26.45B |
Related stock screener links
About SIBN
Company Profile
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Company Info
SI-BONE INC
471 El Camino Real, Suite 101
Santa Clara CALIFORNIA 95050 US
CEO: Jeffrey W. Dunn
Employees: 349
Phone: 14082070700
SI-BONE INC / SIBN FAQ
What is the stock price of SI-BONE INC today?
The current stock price of SIBN is 15.46 USD. The price increased by 1.05% in the last trading session.
What is the ticker symbol for SI-BONE INC stock?
The exchange symbol of SI-BONE INC is SIBN and it is listed on the Nasdaq exchange.
On which exchange is SIBN stock listed?
SIBN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SI-BONE INC stock?
15 analysts have analysed SIBN and the average price target is 25.39 USD. This implies a price increase of 64.21% is expected in the next year compared to the current price of 15.46. Check the SI-BONE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SI-BONE INC worth?
SI-BONE INC (SIBN) has a market capitalization of 658.75M USD. This makes SIBN a Small Cap stock.
How many employees does SI-BONE INC have?
SI-BONE INC (SIBN) currently has 349 employees.
What are the support and resistance levels for SI-BONE INC (SIBN) stock?
SI-BONE INC (SIBN) has a support level at 15.28 and a resistance level at 17.39. Check the full technical report for a detailed analysis of SIBN support and resistance levels.
Is SI-BONE INC (SIBN) expected to grow?
The Revenue of SI-BONE INC (SIBN) is expected to grow by 17.83% in the next year. Check the estimates tab for more information on the SIBN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SI-BONE INC (SIBN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SIBN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SIBN, evaluating the profitability, health, valuation and growth aspects
- SI-BONE INC (SIBN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SI-BONE INC (SIBN) Sales and EPS estimates to see what analysts future expectations are.
- SI-BONE INC (SIBN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SI-BONE INC (SIBN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SI-BONE INC (SIBN) Stock Chart to make your own analysis
- SI-BONE INC (SIBN) Latest news and press-releases to stay up to date.
Does SI-BONE INC (SIBN) stock pay dividends?
SIBN does not pay a dividend.
When does SI-BONE INC (SIBN) report earnings?
SI-BONE INC (SIBN) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of SI-BONE INC (SIBN)?
SI-BONE INC (SIBN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
What is the Short Interest ratio of SI-BONE INC (SIBN) stock?
The outstanding short interest for SI-BONE INC (SIBN) is 4.96% of its float. Check the ownership tab for more information on the SIBN short interest.
SIBN Technical Analysis
SIBN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SIBN. The financial health of SIBN is average, but there are quite some concerns on its profitability.
SIBN Financial Highlights
Over the last trailing twelve months SIBN reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 44.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.68% | ||
| ROE | -15.87% | ||
| Debt/Equity | 0.21 |
SIBN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to SIBN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 15.02% and a revenue growth 17.83% for SIBN